Skip to main content
. 2021 Mar 15;12(10):2835–2843. doi: 10.7150/jca.57429

Figure 3.

Figure 3

Receiver operating characteristic curves (ROCs) of Pro-SFTPB, CA125, Cyfra21-1, CEA, biomarker panel, and nodule risk model (biomarker panel + nodule size) for all lung cancer patients in the training cohort (A) & validation cohort (B).